Onkolytische Viren

Onkolytische Viren können Tumorzellen infizieren und lysieren, sie können aber auch eine spezifische Immunantwort triggern und so suppressiv auf den Tumor wirken. Dieser Beitrag fasst den Stand der onkolytischen Virotherapie beim metastasierten Melanom zusammen.

• Literatur

• 1 Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer 2016; 114: 357-361
• 2 Trager MH, Geskin LJ, Saenger YM. Oncolytic viruses for the treatment of metastastatic melanoma. Curr Treat Options Oncol 2020; 21: 26
• 3 Fu LQ, Wang SB, Cai MH. et al. Recent advances in oncolytic virus-based cancer therapy. Virus Res 2019; 270: 197675
• 4 Fachinformation Imlygic®, aktueller Stand.
• 5 Kiecker F. Virus zur onkolytischen Therapie. PA Onkol Hämatol 2019; 2 (01) 38-39
• 6 Hoeller C, Michielin O, Ascierto PA. et al. Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother 2016; 65: 1015-1034
• 7 Senzer NN, Kaufman HL, Armatruda T. et al. Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. J Clin Oncol 2009; 27: 5763-5771
• 8 Bayan CY, Lopez AT, Gartrell RD. et al. The role of oncolytic viruses in the treatment of melanoma. Curr Oncol Rep 2018; 20: 80
• 9 Andtbacka RH, Collichio F, Harrington KJ. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 2019; 7: 145
• 10 Andtbacka RH, Kaufman HL, Collichio F. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780-2788
• 11 Kohlhapp FJ, Broucek JR, Hughes T. et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer 2015; 3: 18
• 12 Chesney J, Puzanov I, Collichio F. et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2018; 36: 1658-1667
• 13 Geskin L, Brown CR, Kirkwood JM. Adjuvant therapy of melanoma. Semin Cutan Med Surg 2003; 22: 55-67
• 14 Dummer R, Hyngstrom JR, Berger AC. et al One-year (yr) recurrence-free survival (RFS), from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). 2019 . Available at adisinsight.springer.com/trials/700248413
• 15 Rothermel LD, Zager JS. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?. Expert Opin Biol Ther 2018; 18: 1199-1207
• 16 Kageshita T, Yoshii A, Kimura T. et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993; 53: 4927-4932
• 17 Eissa IR, Naoe Y, Bustos-Villalobos I. et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol 2017; 7: 149
• 18 Andtbacka RHI, Ross MI, Agarwala SS. et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J Clin Oncol 2017; 35 (Suppl. 15) 9510
• 19 Speck T, Heidbuechel JPW, Veinalde R. et al. Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res 2018; 24: 2128-2137
• 20 Maroun J, Muñoz-Alía M, Ammayappan A. et al. Designing and building oncolytic viruses. Future Virol 2017; 12: 193-213